🟥 Member Webinar : Hemophilia Alliance Presents - Big Bill, Big Insurance Impact Webinar
2025-08-12 13:00 - 14:00 (America/New_York)
Date: Tuesday, August 12th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TITLE:
Big Bill, Big Insurance Impact – What do HTCs need to know now about coming health insurance changes and how to prepare?
SESSION OBJECTIVE:
The One Big Beautiful Bill Act and other Washington policies are reshaping the insurance landscape for HTCs and their patients with Medicaid and ACA coverage, starting as soon as later this month! Please join The Hemophilia Alliance for this essential new webinar series, kicking off with a comprehensive overview of the coming policy changes. We will also provide strategies for HTCs to start to prepare and advocate to help patients maintain vital coverage. Future sessions will tackle specific policy and HTC operational challenges in detail.
INTENDED AUDIENCE:
All HTC staff
SPEAKERS:
Johanna Gray, Hemophilia Alliance Federal Policy Advisors, Artemis Policy Group

Johanna Gray serves the Hemophilia Alliance as a federal policy advocacy consultant. She has more than a decade of experience in health policy and government relations, working with clients to develop and implement successful advocacy strategies involving Congress and federal public health agencies. Johanna’s clients include patient advocacy groups, physician specialty societies, and associations of specialized treatment centers.
Johanna’s expertise in health policy ranges from the broadly applicable private insurance market reforms included in the Affordable Care Act (ACA) to the specifics of Medicare reimbursement for particular physician services. During the ACA negotiations, Johanna led a coalition of seventy patient advocacy groups and other supporters, which successfully advocated for the elimination of lifetime limits on private health insurance in the law.
Having began her career as an intern for then-Senator Barack Obama, Johanna held several policy analysis and advocacy positions before joining CRD. Johanna received a Master of Public Administration and Certificate in Health Services Management and Policy from the Maxwell School at Syracuse University and a B.A. in Public Policy Studies with honors from the University of Chicago.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Pfizer On Subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience
2025-08-27 14:00 - 15:00
Date: Wednesday, August 27th, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TITLE:
Juggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience.
OBJECTIVES:
To educate attendees on challenges, shared decision making in hemophilia and introduce HYMPAVZI pen, dosage, administration, and real-world patient experience with HYMPAVZI.
AUDIENCE:
All HTC Staff, Physicians, Nurses, Pharmacists, etc.
SPEAKER:
Steven Pipe, MD.
Dr. Steven Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan, Ann Arbor, Michigan, USA. He is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy. He was the 2015 recipient of the Leadership in Research Award from the National Hemophilia Foundation. He has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network and most recently as Chair of the Medical and Scientific Advisory Council to the National Hemophilia Foundation.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From BioMarin On Advancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence, Patient Perspective & Contract Opportunities
2025-09-04 13:00 - 14:00
Date: Thursday, September 4th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TITLE:
Advancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence, Patient Perspective & Contract Opportunities.
OBJECTIVES:

Explore updates to HEM Alliance member contract terms and the associated provider economics.
Review the latest clinical data updates, describing the long-term efficacy and safety of ROCTAVIAN.
Hear a firsthand experience from a patient who has received ROCTAVIAN, offering valuable insights into the real-world impact of this therapy.

AUDIENCE:
All HTC Staff.
SPEAKERS:

Dawn St Amand, Associate Director, BioMarin Medical Science Liaison Hemophilia
Sophie Synder, Director, BioMarin US Value and Access
Andrew W., ROCTAVIAN Patient Experience

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From BD SUMHAC - Mental Health and Substance Use in the Bleeding Disorders Community
2025-09-10 13:00 - 14:00
Date: Wednesday, September 10th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TITLE:
Mental Health and Substance Use in the Bleeding Disorders Community.
DESCRIPTION:
The bleeding disorders community does not have the same access to inpatient and residential mental health and substance use treatment that the general population does. This webinar will talk about the barriers to access the BD community faces and the strategies and resources available to support HTC providers in addressing their patients’ mental health and substance use needs. It will also encourage HTC providers to ask their patients about mental health and substance use concerns early and often and advocate on their behalf when necessary.
OBJECTIVES:

To describe the mental health and substance use needs of the bleeding disorders community.
To outline the barriers to inpatient and residential mental health and substance use treatment the bleeding disorders community .
To provide data demonstrating that HTC provider advocacy on behalf of patients can overcome barriers to access.
To share tools and resources to support your patients’ behavioral health journey and assist in getting people with bleeding disorders access to mental health and substance use care.

AUDIENCE:
All HTC Providers.
SPEAKERS:
Kate Bazinsky, MPH.
Kate Reinhalter Bazinsky has spent over two decades working in health policy and advocacy at the federal, state, and local levels. When her son was diagnosed with severe hemophilia A, she became a passionate advocate for the bleeding disorders community. She co-founded and now serves as the Chair of the Bleeding Disorders Substance Use & Mental Health Access Coalition (BD SUMHAC). BD SUMHAC is a national, multi-stakeholder coalition committed to ensuring equitable access to appropriate substance use and mental health treatment facilities for all individuals with bleeding disorders, with a focus on inpatient and residential facilities. Kate has a Master of Public Health from Johns Hopkins University, She lives in Wellesley, MA with her husband and two children.

Lucy Ramirez, LCSW.
Lucy Ramirez is a licensed clinical social worker for the Rush Hemophilia and Thrombophilia Treatment Center at the Rush University Medical Center in Chicago, Illinois. In her current position, Ms. Ramirez’s practice primarily involves counseling and educating individuals with bleeding disorders, their caregivers and family members. She has served as facilitator and guest speaker for patient educational events sponsored by the National Bleeding Disorders Foundation, the Bleeding Disorder Alliance of Illinois, the VWD Connect Foundation and the Coalition for Hemophilia B. She serves as the current vice chair of the National Bleeding Disorders Foundation’s Social Work Working Group.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Sanofi - Qfitlia Overview - Clinical, Access, and Distribution Dynamics
2025-09-17 14:00 - 15:00
Date: Wednesday, September 17th, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TOPIC:
Qfitlia Overview: Clinical, Access, and Distribution Dynamics.
OBJECTIVE:
Dr. Lynn Malec will review key elements of the Qfitlia efficacy and safety profile and Adam Gurry, Sanofi Director of Access Strategy, will provide insights on the Qfitlia access and distribution strategy.
AUDIENCE:
All HTC Providers and Staff.
SPEAKERS:

Lynn Malec, MD. received her undergraduate and medical school degrees from the University of Wisconsin, and went on to complete a residency in Internal Medicine and Pediatrics followed by a Pediatric Hematology/Oncology fellowship at the University of Pittsburgh/Children’s Hospital of Pittsburgh. Currently, Dr. Malec is an Associate Investigator at the Versiti Blood Research Institute and Assistant Professor of Medicine and Pediatrics at the Medical College of Wisconsin. Dr. Malec serves as the Medical Director of the Comprehensive Center for Bleeding Disorders at Versiti. She is actively engaged in the care and research involving both adults and children with hemophilia and other bleeding and clotting disorders; her specific area of clinical research is focused on inhibitors in hemophilia and the impact of new factor products.
Adam Gurry, Director of Access Strategy at Sanofi has 19 years of experience on the commercial side of the business holding various roles of increasing responsibility. The past 5 years Adam has been focused on the Rare Blood therapeutic area responsible for the development of payer facing marketing materials and recently led the development of Qfitlia’s access strategy.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Takeda - On-demand and Surgical Use of ADVATE® [Antihemophilic Factor (Recombinant)]
2025-10-01 13:00 - 14:00
Date: Wednesday, October 1st, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
On-demand and Surgical Use of ADVATE® [Antihemophilic Factor (Recombinant)]
OBJECTIVE:
This session will explore critical aspects of hemophilia A management, focusing on the unique role of ADVATE in on-demand and perioperative settings.
AUDIENCE:
All HTC Staff.
SPEAKER:
Jessica Grandoni, Pharm.D., BCPS, was the Hemostatic Antithrombotic Stewardship Lead Pharmacist (HAT), and clinical pharmacy specialist, at Brigham and Women’s Hospital in Boston, Massachusetts. She is now a clinical pharmacy specialist at the Dana Farber Cancer Institute’s Anticoagulation Management Service.
Jessica has been involved in several committees and initiatives related to her practice interests of anticoagulation therapy and reversal, heparin induced thrombocytopenia, mechanical circulatory support, drug formulary management and associated guidelines. She is involved in research, education, and publications with pharmacy, hematology, cardiology, and the mechanical circulatory support division. She has published one of the top downloaded articles with the American Journal of Hematology and has presented at national and international conferences. Jessica earned her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences University in Boston and completed an ASHP-accredited Post Graduate Year 1 residency at Beth Israel Deaconess Medical Center. She also completed an ASHP-accredited Post Graduate Year 2 cardiology residency at The University of California Davis Medical Center with a focus in anticoagulation and reversal.

🟥 Member Event : 2025 Fall Members Meeting & Hill Day
2025-10-05 18:30 - 2025-10-07 17:30
Date: October 5 – 7, 2025
Location: Washington, DC
Agenda Overview

Sunday, October 5th – Networking Reception 6:30pm – 8:30pm
Monday, October 6th – Breakfast at 7:30am, followed by Meeting 8:30am – 6:30pm, to include our Hill Day Training and Dinner to follow
Tuesday, October 7th – Breakfast then Hill Day (schedules TBD)

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Octapharma - Prophylaxis in VWD: Iron as a Metric of Success at Healing
2025-10-15 14:00 - 15:00
Date: Wednesday, October 15th, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TOPIC:
Prophylaxis in VWD: Iron as a Metric of Success at Healing.
WEBINAR SUMMARY:
A presentation on rethinking prophylaxis in VWD through a lens of healing and iron status.
This presentation explores a multidimensional approach to bleeding disorders, with a focus on von Willebrand Disease (VWD), the evolving role of prophylaxis, and iron deficiency as a measurable indicator of treatment success. By reframing bleeding disorders as healing disorders, we challenge traditional paradigms and highlight the importance of patient-centered care.
Through clinical insights and emerging data, we examine how iron status can serve as a proxy for bleeding control, and how prophylactic strategies are reshaping outcomes across all types of VWD. This session invites clinicians, researchers, and educators to consider new metrics and models that better reflect the lived experiences of patients and the true impact of therapeutic interventions.
AUDIENCE:
All HTC Staff.
SPEAKER:
Amber Federizo, DNP
Born and raised in the rural heart of Nevada, she has long been driven by a deep commitment to serving those who are often overlooked or underserved. For over a decade, she provided compassionate diagnosis and treatment to patients of all ages at Nevada’s Hemophilia Treatment Center (HTC), with a particular focus on addressing the unique challenges faced by women in the bleeding disorders community. Her unwavering dedication and authentic approach have brought light and hope to vulnerable populations both domestically and internationally.
In recognition of her impactful work, Amber was honored in 2018 as the Humanitarian of the Year by the National Hemophilia Foundation (now known as the National Bleeding Disorders Foundation). Through research, education, and advocacy, she continues to forge new pathways and expand opportunities for individuals and families affected by bleeding disorders.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Genentech - Revolutionizing Hemophilia A Care: Nurses’ Insights on the First Subq Prophy for Hem A
2025-10-23 15:00 - 16:00
Date: Thursday, October 23rd, 2025
Time: 3:00pm – 4:00pm ET

WEBINAR TITLE:
Revolutionizing Hemophilia A Patient Care: Nurses’ Insights on the First Subcutaneous Prophylaxis Treatment for Hemophilia A.
DESCRIPTION:
Please join us for an engaging discussion featuring nurses Jennifer Maahs, RN, PNP, MSN and Joseph Stanco, MSN, DNP, CCRC as they share their perspectives on the evolution of hemophilia A management. We’ll celebrate the personal and collective experiences of nurses and their crucial role in the patient’s treatment journey with the first subcutaneous prophylaxis treatment for hemophilia A. Test your knowledge with trivia while discovering the impact of a treatment with over a decade of clinical trial experience, as the presentation highlights expert clinical practice insights, pivotal efficacy and safety data, and long-term outcomes, including data in infants. Please bring your questions to have them answered live in the Q&A following the program.
AUDIENCE:
All HTC Staff.
SPEAKERS:

Jennifer Maahs, RN, PNP, MSN – Jennifer Maahs is a Pediatric Nurse Practitioner at the Indiana Hemophilia and Thrombosis Center, a role she has held since 1993. She earned her MS in Nursing as a Pediatric Nurse Practitioner from Indiana University and a Bachelor of Science in Nursing from The Ohio State University. Her expertise lies in research, education, and patient care for hemophilia, hemostasis, and thrombosis-related complications. Ms. Maahs is actively involved in developing and implementing educational programs for medical care providers in the bleeding disorder community, has served on numerous committees and advisory boards, and is currently the US representative for the World Federation of Hemophilia.
Joseph Stanco, MSN, DNP, CCRC – Joseph Stanco is a Doctor of Nursing Practice. As a family nurse practitioner he cares for children and adults with bleeding disorders as well as leading various research as the nurse coordinator of the Northwell Health Hemostasis and Thrombosis Center. Beyond his caring for patients, Joe is the president Hemostasis and Thrombosis Nursing Association, Executive Committee Member of the New England Hemophilia Region, New England representative of the NBDF Nursing Working Group.
Most recently Joe was awarded Nurse of the year at the 2025 NBDF Bleeding Disorders Conference.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Novo Nordisk - Alhemo (concizumab-mtci): A new option for patients living with hemophilia
2025-10-30 14:00 - 15:00
Date: Thursday, October 30th, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TOPIC:
Alhemo (concizumab-mtci): A new option for patients living with hemophilia.
OBJECTIVE:
To provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors, and supporting data from the explorer8 trial.
AUDIENCE:
All HTC Staff.
SPEAKER:
Ryan Rodriguez, PharmD, MS, BCPS, is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders, aligning with his passion for evidence-based patient care.
Prior to joining Novo Nordisk, Ryan earned his PharmD degree from the University of Florida, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy, where he also earned his Master’s degree in epidemiology. Throughout his career, Ryan has been involved in medical communications, evidence generation and publication, and formulary management for various public and private entities.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Bayer - Jivi - With Them as They Grow™ Clinical Study Data for Children 7 to 11 Yrs
2025-11-06 13:00 - 14:00
Date: Thursday, November 6th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Jivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years.
OBJECTIVE:
This session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data from these studies have been combined, as each included participants aged 7 to less than 12 years. The studies were conducted to evaluate the safety and clinical effectiveness of Jivi in previously treated individuals within this age group who have severe hemophilia A. Get the latest data and learn how Jivi may fit the needs of your patients starting at age 7.
Indications: JIVI ® is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for:

On-demand treatment and control of bleeding episodes.
Perioperative management of bleeding.
Routine prophylaxis to reduce the frequency of bleeding episodes.

Limitations of use JIVI is not indicated for use in:

Children less than 7 years of age due to a greater risk for hypersensitivity reactions and/or loss of efficacy.
Previously untreated patients (PUPs).
Treatment of von Willebrand disease.

AUDIENCE:
All HTC Staff.
SPEAKER:
Dr. Akshat Jain MD, MPH
Director of Sickle Cell Center of Excellence; Faculty Clinical Medicine and Pediatrics; Hematology Oncology and Cell Therapy; Loma Linda University School of Medicine

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - VONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients
2025-11-12 13:00 - 14:00
Date: Wednesday, November 12th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
VONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients.
OBJECTIVE:

Understand the underlying mechanism of VWD and the role of VWF.
Review unmet needs in the treatment of VWD.
Identify the unique characteristics of VONVENDI as the first and only recombinant treatment for patients with VWD.
Review hypothetical patient cases and clinical data for on-demand, prophylactic, and surgical control of bleeds with VONVENDI.

AUDIENCE:
All HTC Staff.
SPEAKER:
Dr. Jonathan Roberts
Dr. Roberts graduated from the Southern Illinois School of Medicine in 2008 and completed his internship and residency in Pediatrics at the University of Illinois College of Medicine at Peoria at OSF HealthCare Children’s Hospital of Illinois in 2011. After finishing his residency, Dr. Roberts completed fellowship in Pediatric Hematology/Oncology/Blood & Marrow Transplantation at the Medical College of Wisconsin/Children’s Hospital of Wisconsin in 2014 and worked as a post-doctoral fellow under Dr. Robert Montgomery and Dr. Joan Cox Gill at the Blood Center of Wisconsin Blood Research Institute. In addition to being the Associate Medical Director/Associate Research Director of BCDI, Dr. Roberts is also an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria, IL.
Dr. Roberts’ research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia, VWD, and other rare bleeding and classical hematologic disorders. He has received numerous young investigator research awards, has over 100 peer-reviewed research publications and abstracts including lead/senior author publications in Blood, the Journal of Thrombosis and Haemostasis, and the New England Journal of Medicine; and has had grant funding from the National Bleeding Disorders Foundation, World Federation of Hemophilia and National Institutes of Health among others.
Dr. Roberts has a personal passion for the bleeding disorders community as he is also an individual with severe hemophilia A.
Disclosures:
Novo Nordisk, Octapharma, Sanofi, Takeda, Genentech, Pfizer, F. Hoffmann-La Roche AG

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - The HEMGENIX Toolkit
2025-11-13 13:00 - 14:00
Date: Thursday, November 13th, 2025
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
The HEMGENIX Toolkit
OBJECTIVE:
Overview of the tools and resources available to treatment centers to help support patients eligible and interested in HEMGENIX
AUDIENCE:
All HTC Staff.
SPEAKER:
Bonnie Ben-Shmuel
Bonnie Ben-Shmuel is a seasoned biopharmaceutical marketing leader with over a decade of experience driving commercial strategy, cross-functional execution, and transformational growth across gene therapy, rare disease, immunology, and oncology. As Director of U.S. Marketing for HEMGENIX, she has led initiatives that expanded treatment center readiness, streamlined patient access, and accelerated gene therapy adoption.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Sanofi - Translating Evidence into Practice: ​Real-World Patient Cases with ALTUVIIIO
2025-12-03 14:00 - 15:00
Date: Wednesday, December 3rd, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TOPIC:
Translating Evidence into Practice: ​Real-World Patient Cases with ALTUVIIIO.
OBJECTIVE:
This session will bring together clinical evidence and real-world experience to illustrate how ALTUVIIIO can optimize treatment and improve outcomes for patients living with Hemophilia A.
AUDIENCE:
All HTC Staff.
SPEAKER:
Vivek Sharma, MD, FACP – Professor of Medicine Division of Hematology/Oncology, University of Louisville

Dr. Sharma is a Professor of Medicine at the University of Louisville at the Division of Hematology/Oncology. He completed his medical school in India and his Internal Medicine Residency as well as Heme/Onc Fellowship at the University of Louisville. He is the Medical Director of the Lifespan Hemophilia program in Louisville and also has interest in other rare hematological diseases.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - New! Real-World Evidence to Support Optimization of Factor IX Prophylaxis
2025-12-11 14:00 - 15:00
Date: Thursday, December 11th, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TITLE:
New! Real-World Evidence to Support Optimization of Factor IX Prophylaxis
SUMMARY:
This webinar will discuss recent evidence on prophylactic treatment strategies for hemophilia B from a U.S. real-world retrospective analysis of factor IX products. The session will highlight factor consumption patterns, bleeding outcomes, and comparative effectiveness following a switch to inform clinical decision-making and optimize patient care.
AUDIENCE:
All HTC Staff.
SPEAKER:

Vidhi Desai, Senior Medical Director (Coagulation), US Medical Affairs
Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Hemgenix®, Idelvion®, Afstyla® and Humate-P®, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team.
Prior to joining CSL Behring, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, focusing primarily on benign hematologic disorders.
Vidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ.

🟥 Member Event : 2026 Medical Providers and Business Administrators Meeting
2026-01-11 18:30 - 2026-01-13 15:30
Date: January 11 – 13, 2026
Location: Newport Beach, CA

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - Five-Year Analysis: Efficacy and Safety of HEMGENIX®
2026-01-15 13:00 - 14:00
Date: Thursday, January 15th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TITLE:
Five-Year Analysis: Efficacy and Safety of HEMGENIX®
SUMMARY:
Presentation of the published efficacy and safety results of the five-year analysis of the HOPE-B clinical trial follow up.
AUDIENCE:
All HTC Staff.
SPEAKER:

Vidhi Desai, Senior Medical Director (Coagulation), US Medical Affairs
Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Hemgenix®, Idelvion®, Afstyla® and Humate-P®, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team.
Prior to joining CSL Behring, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, focusing primarily on benign hematologic disorders.
Vidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ.

🟥 Member Event : 2026 Pharmacists CE Conference
2026-01-21 18:30 - 2026-01-23 15:30
Date: January 21 – 23, 2026
Location: Tampa, FL

Please contact Theresa Parker with any questions regarding this application at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Event : 2026 Linda Gammage Social Workers CE Conference
2026-02-25 18:30 - 2026-02-27 15:30
Date: February 25 – 27, 2026
Location: Oklahoma City, OK

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Overview of Patient Tools & Support Resources
2026-03-05 13:00 - 14:00
Date: Thursday, March 5th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Overview of Patient Tools & Support Resources.
OBJECTIVE:
This presentation will provide an overview of Takeda Hematology Patient tools and Support resources and education on the navigation of these tools and resources.
AUDIENCE:
All HTC Staff.
SPEAKERS:
Carley Riehle – Specialty Pharmacy National Account Director, HEM Alliance Account Lead

Katrina McGrath – Community Education Lead for US HEM Franchise

Nicole Loguidice – Associate Director for Hematology Patient Access Operations

Erik Evans – Regional Director for Rare Diseases/PDT Patient Access – Field

🟥 Member Event : 2026 Spring Members Meeting
2026-03-08 18:30 - 2026-03-10 15:30
Date: March 8 – 10, 2026
Location: Seattle, WA

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances
2026-03-12 13:00 - 14:00
Date: Thursday, March 12th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances.
OBJECTIVE:
After this webinar, participants will be able to:

Describe the clinical impact and risk factors for FVIII inhibitor development in Previously Untreated Patients (PUPs)
Summarize key findings from past PUP studies, including the SIPPET trial
Review Phase 3 PUP trial data for rurioctocog alfa pegol
Discuss implications for monitoring and managing inhibitor risk in current clinical practice

AUDIENCE:
All HTC Staff.
SPEAKERS:

Caitlin Montcrieff, MSN, CPNP – Director, US Medical Hematology & Rare Disease

Robert Sidonio, MD, MSc
Dr. Robert F. Sidonio, Jr, MD, MSc is a Professor of pediatrics at Emory University School of Medicine and the Medical Director of the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory. Dr. Sidonio’s clinical and research interests are in the management of pediatric patients with bleeding disorders. His research focus has included women with bleeding disorders, von willebrand disease and the study of inhibitor development in patients with Hemophilia A. Dr. Sidonio was the principal investigator for the Phase 3 clinial trial of rurioctocog alfa pegol in previously untreated patients with Hemophilia A.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from BrightStar Care - BrightStar Franchising Nursing Care Agreement
2026-03-31 13:00 - 14:00
Date: Tuesday, March 31st, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
BrightStar Franchising, LLC Master Service Agreement for Nursing Services Now Available to Hemophilia Alliance Member Hemophilia Treatment Centers.
OBJECTIVES:

Understand the services of BrightStar Franchising, LLC. And what services are available to Hemophilia Alliance member HTCs under the Master Service Agreement

Who is BrightStar Franchising, LLC
What services are available through this Master Services Agreement to Hemophilia Treatment Centers (HTC)
What states are BrightStar Franchises located/not located
How do HTCs access the BrightStar local agencies for services

Review of the key aspects of the Master Service Agreement

Key considerations for HTCs
Key considerations for BrightStar Franchises

AUDIENCE:
All HTC Staff.
SPEAKERS:

Wil Cabrera, MBA
VP, National Accounts

Debra Smith, MBA HCM
Sr. Director, Centralized Intake Operations

Joshua Allen, RN
Sr. Director Infusion Services

🟥 Member Event : 2026 New HTC Staff Meeting
2026-04-21 18:30 - 2026-04-23 15:30
Date: April 21 – 23, 2026
Location: Aurora, CO

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Sanofi - Targeted Multi-Immune Modulation in ITP
2026-04-28 16:30 - 17:30
Date: Tuesday, April 28th, 2026
Time: 4:30pm – 5:30pm ET

WEBINAR TOPIC:
Targeted Multi-Immune Modulation in ITP
DESCRIPTION:
This event will provide an overview of a multi-immune modulator that helps address the complex immune dysregulation in immune thrombocytopenia (ITP). The presentation will highlight key aspects of the disease pathophysiology, the potential benefits of a multi-immune modulator and clinical trial evidence in ITP patients.
AUDIENCE:
All HTC Staff.
SPEAKER:

Michael Tarantino, MD
Dr. Tarantino has more than 30 years of experience in hematology, as well as 14 years of experience as the Founder, Chief Medical Officer and Chief Executive Officer of the Bleeding & Clotting Disorders Institute. For over three decades he has devoted his medical career to the management of bleeding and blood clotting disorders, as well as non-malignant hematology disorders.
Dr. Tarantino also serves as the Medical Director of the Anticoagulation Consultation Service at St. Francis Medical Center. Since 2008, Dr. Tarantino is a tenured Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria and is active in teaching medical students, residents and allied health professionals.
Dr. Tarantino earned a Doctor of Medicine degree from the University of Wisconsin School of Medicine and Public Health in 1987. He then completed a residency in pediatrics from the University of Arizona in 1990 and a fellowship in pediatric hematology and oncology from the University of Wisconsin in 1993.
Dr. Tarantino is board certified in Pediatric Hematology and Oncology. He is the chairman of the Medical Advisory Board of the Platelet Disorder Support Association and served as a member of the Medical Advisory and Scientific Council of the National Bleeding Disorders Foundation from 2012-2022. In 2005 and 2017 Dr. Tarantino received the Research Excellence Award from the University of Illinois College of Medicine, and in 2012 and 2018 he was awarded the Physician of the Year and the Excellence in Healthcare Award, respectively, from the National Bleeding Disorders Foundation. In 2024, Dr. Tarantino was honored to receive a Lifetime Achievement Award from NBDF for his dedicated career of improving the lives of individuals with bleeding disorders- helping them live longer lives while empowering them to become their own advocates.
Dr. Tarantino has had an active career in clinical and translational research. As a result, he has authored or co-authored over 125 peer-reviewed papers, reviews and book chapters, in addition to over 140 scientific abstracts.

🟥 Member Event : 2026 Nurses CE Meeting
2026-05-03 18:30 - 2026-05-05 15:30
Date: May 3 – 5, 2026
Location: Chicago, IL

Please note: this application button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Event : 2026 Physical Therapists CE Meeting
2026-05-06 18:30 - 2026-05-08 15:30
Date: May 6 – 8, 2026
Location: Chicago, IL

Please note: this application button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Octapharma - Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
2026-05-12 13:00 - 14:00
Date: Tuesday, May 12th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
OBJECTIVES:

Heavy menstrual bleeding (HMB) is one of the most common and underrecognized manifestations of von Willebrand disease (VWD) and represents a significant cause of iron deficiency and iron deficiency anemia in affected women. Chronic blood loss associated with HMB can lead to fatigue, impaired cognitive and physical functioning, reduced quality of life, and increased healthcare utilization. Despite its prevalence, both VWD and iron deficiency related to HMB are frequently underdiagnosed and undertreated.
This webinar will provide a focused clinical overview of HMB in the context of VWD, emphasizing the interconnected relationship between abnormal bleeding and iron deficiency. Participants will review the burden of disease, diagnostic considerations, and treatment goals aimed at controlling bleeding while addressing its systemic consequences. The program will also highlight Wilate®, a VWF/FVIII concentrate, including its clinical profile, supporting evidence, and practical application in the management of HMB associated with VWD. Finally, the webinar will explore Wilate’s clinical and therapeutic value proposition, with an emphasis on optimizing outcomes and improving quality of life for women living with VWD-related HMB.

AUDIENCE:
All HTC Staff.
SPEAKER:

Claudio Sandoval, MD – Senior Director, Scientific and Medical Affairs – Hematology Octapharma USA
Claudio Sandoval is the Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders, cancer, sickle cell disease, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park, NY and St. Jude Children’s Research Hospital in Memphis, TN.

🟥 Member Webinar : Hemophilia Alliance Hosts - An Update on Takeda’s Transformation, Supply Status, and Hemophilia A Treatments
2026-07-22 13:00 - 14:00
Date: Wednesday, July 22nd, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
An Update on Takeda’s Transformation, Supply Status, and Hemophilia A Treatments
OBJECTIVES:

To familiarize audiences with Takeda transformation update
To share reminder on the HEMOFIL® M & RECOMBINATE® supply status
To share HCP presentation focusing on the immunogenicity results of the ADYNOVATE phase 3 trial in previously untreated patients (PUPs) and attributes of ADVATE for previously treated patients (PTPs).

AUDIENCE:
All HTC Staff
SPEAKERS:
Dr. Jonathan Roberts is the Associate Medical Director and Associate Research Director at the Bleeding and Clotting Disorders Institute in Peoria, IL. He also serves as an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria, IL.
Dr. Roberts’ research focuses on developing novel laboratory assays to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia, VWD, and other rare bleeding disorders. He has received numerous young investigator research awards and has authored over 100 peer-reviewed research publications and abstracts. His work includes lead and senior author publications in prominent journals such as Blood, the Journal of Thrombosis and Haemostasias, and the New England Journal of Medicine. He has also secured grant funding from organizations such as the National Bleeding Disorders Foundation, the World Federation of Hemophilia, and the National Institutes of Health.

Carley Riehle has been with Takeda for nearly nine years and has built her career around supporting the bleeding disorder community. She began in the field, calling on HTCs, hospitals, and chapters before leading a team of field members, where she developed a deep appreciation for the strength and resilience of the community. She later transitioned to Takeda’s Payer Team, where she focused on creating and protecting access for patients on Takeda therapies. Most recently, Carley was promoted to National Director of Specialty Pharmacy, where she partners with national specialty pharmacies and the Hemophilia Alliance to strengthen Takeda’s relationships, support their members, and ultimately improve access for patients. She is passionate about building trusted partnerships and advancing meaningful support for the bleeding disorder community.

Natalie Wu, Head of Takeda’s US Hematology and Transplant Franchise is biopharmaceutical leader with over 25 years of diverse US and Global experience across Rare Diseases, Oncology, Diabetes, and Neuroscience. Natalie is passionate about building deep connections with the patient communities we serve and the healthcare and advocacy teams who work tirelessly to support patients in their quest for better health. She challenges the status quo to drive meaningful impact where unmet needs and heath inequities remain.

Nicole Loguidice, MBA is Director, Foundational Therapeutics Platform Access Operations at Takeda. With more than eight years of experience in patient access, she has led operations across Hematology, Rare Disease, Endocrinology, and Transplant programs. Nicole is passionate about developing patient-centered access solutions, fostering cross-functional collaboration, and advancing programs that support patients’ access to the therapies they need.

🟥 Member Webinar : Hemophilia Alliance Presents - A Webinar on Planning for Medicaid Work Requirements
2026-07-30 14:00 - 15:00
